Recent Examples of China Strategy Success
EsoBiotec (often styled EsoBiotec/Esobiotec in media) and ProfoundBio both used China as a critical pillar in their R&D and clinical strategies. EsoBiotec relied on a focused China trial and manufacturing collaboration to validate a single in vivo CAR‑T program, whereas ProfoundBio built a broader U.S.–China hybrid organization with an R&D base in Suzhou that underpinned […]